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One of the main tasks of the immune system is to discriminate and appropriately react to 
“danger” or “non-danger” signals. This is crucial in the gastrointestinal tract, where the 
immune system is confronted with a myriad of food antigens and symbiotic microflora 
that are in constant contact with the mucosa, in addition to any potential pathogens. This 
large number of antigens and commensal microflora, which are essential for providing 
vital nutrients, must be tolerated by the intestinal immune system to prevent aberrant 
inflammation. Hence, the balance between immune activation versus tolerance should 
be tightly regulated to maintain intestinal homeostasis and to prevent immune activation 
indiscriminately against all luminal antigens. Loss of this delicate equilibrium can lead to 
chronic activation of the intestinal immune response resulting in intestinal disorders, such 
as inflammatory bowel diseases (IBD). In order to maintain homeostasis, the immune 
system has evolved diverse regulatory strategies including additional non-immunological 
actors able to control the immune response. Accumulating evidence strongly indicates 
a bidirectional link between the two systems in which the brain modulates the immune 
response via the detection of circulating cytokines and via direct afferent input from 
sensory fibers and from enteric neurons. In the current review, we will highlight the most 
recent findings regarding the cross-talk between the nervous system and the mucosal 
immune system and will discuss the potential use of these neuronal circuits and neuro-
mediators as novel therapeutic tools to reestablish immune tolerance and treat intestinal 
chronic inflammation.
Keywords: intestinal immune system, oral tolerance, sympathetic system, parasympathetic system, peptidergic 
pathway, neuropeptide, inflammatory bowel disease
iNTeSTiNAL iMMUNe HOMeOSTASiS AND ORAL TOLeRANCe
A main function of the immune system is to distinguish between “danger” or “non-danger” signals 
and to respond appropriately. This is crucial in the gastrointestinal (GI) tract, where the immune 
system is constantly exposed to a multitude of food antigens and symbiotic microflora, which are 
essential for providing vital nutrients to the body. Therefore, the balance between immune acti-
vation versus tolerance should be tightly regulated to maintain intestinal homeostasis. In recent 
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years, it has become clear that the mucosal immune system has 
developed an ingenious mechanism, referred to as oral tolerance, 
to fulfill this task. In detail, lamina propria antigen-presenting 
cells (APCs), such as dendritic cells (DCs) and macrophages 
(MFs), are “educated” by intestinal bioactive factors, such as 
transforming growth factor-beta (TGF-β), retinoic acid, thymic 
stromal lymphopoietin, and mucins (1–5), to suppress inflam-
mation and promote immunological tolerance via the induction 
and expansion of antigen specific anti-inflammatory regulatory T 
cells (Tregs) in the mesenteric lymph nodes (MLN).
To date, oral tolerance is widely accepted to represent the 
cornerstone of intestinal immune homeostasis (3, 6). In healthy 
individuals, intestinal immune tolerance against food and micro-
biota antigens is, therefore, crucial to prevent an immune reac-
tion against harmless food (3). Nevertheless, in individuals with 
genetic or environmental predisposition (altered microbiota, viral 
or bacterial infection, chemical additives, or pollution) oral toler-
ance is broken resulting in immune activation against luminal 
antigens. Loss of this delicate equilibrium indiscriminately results 
in chronic and excessive immune activation indiscriminately 
against luminal antigens leading to invalidating intestinal disor-
ders, such as inflammatory bowel disease (IBD). So far, there is 
no cure for IBD. The actual goal of IBD treatment is to reduce the 
inflammation that triggers symptoms and tissue alterations. In a 
group of cases, this may lead to long-term remission and reduced 
risks of complications but in a large number of patients disease 
relapses are common. Thus, the ultimate aim in IBD research is to 
explore novel therapeutic methods to reinstall intestinal immune 
tolerance.
Lately, experimental and clinical evidence suggests that an 
additional actor, i.e., the nervous system, may play a critical 
role in modulating the intestinal microenvironment, preserving 
immune homeostasis and tolerance. In the current review, we 
will highlight the most recent findings regarding the cross-talk 
between the nervous system and the mucosal immune system. 
Furthermore, we will discuss the potential employment of some of 
these neuronal circuits and neuromediators as novel therapeutic 
tools to reestablish immune tolerance and treat intestinal chronic 
inflammatory diseases, such as IBD.
THe NeRvOUS SYSTeM AS MODULATOR 
OF iMMUNe ReSPONSe
The cross-talk between the immune and nervous systems occurs 
through a complex set of neurotransmitters, cytokines and 
hormones and is undoubtedly playing a crucial role in the regula-
tion of an immune response (7). The ground-breaking idea that 
neurotransmitters could serve as immune modulators emerged 
with the discovery that their release and diffusion from nervous 
tissue could lead to signaling through typical neurotransmitter 
receptors expressed on immune cells (8).
Inflammatory mediators released locally can activate sensory 
nerves and send signals to the nervous system. Through the 
induction of the so called “inflammatory reflex,” efferent nerves 
also convey signals from the nervous system to the periphery 
where the release of neural mediators affects immune responses 
and inflammation (9). Consequently, the nervous system is able 
to rapidly sense and regulate inflammation in peripheral tissues 
as well as restore immune homeostasis via the release of media-
tors acting locally on immune cells. In several chronic inflamma-
tory diseases such as rheumatoid arthritis (RA), systemic lupus 
erythematosus, and IBD, the tone of the sympathetic nervous 
system (SNS) is also increased (10). This suggests that an auto-
nomic nervous system imbalance with a dominant activation of 
the SNS and inadequate parasympathetic tone may have a key 
role in the pathogenesis of various immune related disorders 
including IBD (11).
NeUROiMMUNe iNTeRACTiON iN THe 
GUT wALL
The enteric nervous system (ENS), also known as the “Little brain 
of the gut,” forms a complex and independent nervous system 
within the GI tract (12). The ENS, together with the assistance of 
the extrinsic innervation, enables us to perceive the inner world 
of our intestine and its contents, to regulate motility and to digest 
nutrients (12) (Figures 1A,B).
The ENS consists of a network of hundreds of millions of neu-
rons and glial cells clustered in small ganglia connected by nerve 
bundles organized in two major layers embedded in the gut wall, 
the myenteric plexus (or Auerbach’s plexus) and the submucosal 
plexus (or Meissner’s plexus) (13, 14).
Functionally, the ENS resembles the central nervous system 
(CNS) as it uses similar sensory and motor neuronal fibers, 
information processing circuits “or interneurons” and releases 
a comparable set of neurotransmitters (Figure 2). The chemical 
neuromediators of the ENS were initially thought to be limited to 
neurotransmitters, such as acetylcholine (ACh) and serotonin, but, 
subsequently, purines, such as ATP, amino acids (γ-aminobutyric 
acid or glutamate), and peptides, such as vasoactive intestinal 
polypeptide (VIP) and neuropeptide Y (NPY), have been identi-
fied (15). More recently, nitric oxide (NO) has emerged as an 
important neurotransmitter in the ENS (16, 17). Overall, more 
than 20 candidate neurotransmitters have now been identified in 
ENS, and most neurons contain several of them (15). Growing 
evidence now supports the ground-breaking idea that these neu-
rotransmitters can convey signals to immune cells and modulate 
their function (8). Indeed, many neurally derived molecules, such 
as ACh, serotonin and glutamate, have potent inhibitory effects 
on various immune cells including APCs or T cells (8, 18).
Besides the intrinsic innervation, the gut is extrinsically inner-
vated by the autonomic nervous system composed of the sym-
pathetic (SNS) and parasympathetic (PNS) system (Figure  2). 
Cell bodies of preganglionic sympathetic neurons are located in 
the CNS, between the first thoracic and third lumbar spinal cord 
segment, from where its axon connects to the postganglionic neu-
rons where they send axons to the intestinal wall. On the contrary, 
parasympathetic preganglionic neurons are found directly in the 
brainstem were they form the vagus nerve (VN) that densely 
innervates the GI tract.
Sympathetic and parasympathetic fibers convey afferent infor-
mation from the gut to the brain informing the CNS about the 
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intestinal microenvironment (19). We have recently identified a 
direct activation of neurons (c-fos expression) in the dorsal motor 
nucleus of the VN in a mouse model of intestinal inflammation 
(20). This evidence strongly supports the idea that inflammatory 
stimuli can activate the autonomic nervous system and induce 
the release of immune-modulatory mediators in the periphery 
by nerve endings.
PARASYMPATHeTiC NeRvOUS SYSTeM 
AS MODULATOR OF iNTeSTiNAL 
iMMUNe HOMeOSTASiS
In line with the neuroimmune cross-talk hypothesis, the CNS, via 
the VN, is playing a crucial role in regulating immune response 
in the periphery through the cholinergic anti-inflammatory path-
way (CAIP) (21). Tracey et al. originally reported that vagotomy 
significantly enhanced proinflammatory cytokine production and 
accelerated the development of septic shock, whereas electrical 
FiGURe 1 | immune cells and neuronal fibers are in close proximity in the gastrointestinal tract. Immunofluorescent picture of the ileum (A) and proximal 
colon (B) from CX3CR1eGFP/WT mice showing in red neuronal fibers and in green CX3CR1+ macrophages. Neuronal fibers were visualized with a rabbit antitubulin III 
(red; Covance, 1:2000) followed by a donkey anti-rabbit Cy5 antibody (Jackson Immunoresearch). The green GFP signal (i.e., macrophages) highlights the CX3CR1+ 
macrophages.
stimulation of the efferent VN prevented systemic inflammation 
and improved survival via the release of ACh in the spleen (22, 
23). More recently, they also showed that in sepsis, the vagal anti-
inflammatory reflex requires an intact splenic nerve (23) and alpha 
7 nicotinic receptor (α7nAChR) expression on splenic MFs (24). 
Since the spleen is devoid of cholinergic innervation, this concept 
was lately challenged. However, this discrepancy was resolved by 
showing that upon vagus nerve stimulation (VNS), ACh released 
in the celiac mesenteric ganglia activates postsynaptic α7nAChR 
of the splenic nerve, leading to the release of norepinephrine in 
the spleen (25, 26). Surprisingly, norepinephrine induces the 
synthesis of ACh in a subpopulation of splenic memory T cell 
expressing choline acetyltransferase (ChAT), resulting into the 
anti-inflammatory effect of VNS (27). The discovery that activa-
tion of the VN has a potent anti-inflammatory effect implies that 
afferent vagal fibers will detect activation of the innate immune 
system in peripheral tissue and send an integrated efferent vagal 
input to that same site modulating the inflammatory response. 
FiGURe 2 | A schematic representation of the cross-talk between the nervous and immune system in gastrointestinal tract.  
 (Continued)
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Thus, the CAIP represents a new counter-regulatory mechanism 
to control the immune system and in contrast to circulating 
hormones or cytokines, provide a rapid local modulation of the 
immune response (27).
Early anatomical evidence highlights that efferent vagal nerve 
fibers extensively innervate the GI tract with a typical rostro-
caudal gradient of vagal preganglionic innervation, with the 
highest density observed in the stomach followed by a subsequent 
decrease in the small bowel and colon (28). Therefore, it is not 
surprising that the vagal anti-inflammatory pathway plays a 
crucial role in the regulation of the intestinal immune response.
A few years later, we and others have extended the concept of 
the vagal anti-inflammatory pathway to the GI tract by showing 
the benefical effect of electrical VNS in a model of postoperative 
ileus (POI) (29) (Figure 2). POI is an immune-mediated condi-
tion evoked by surgical handling of the intestine in which the 
inflammation is primarily restricted to the intestinal muscular 
layer. In this model, electrical, nutritional and pharmacological 
activation of CAIP have been shown to prevent both surgery-
induced inflammation and delayed GI transit (29, 30).
Similar to the spleen, we identified α7nAChR-expressing MFs 
residing in the muscularis externa as the final target of vagal 
anti-inflammatory pathway in the gut (Figure 2D) (31, 32). In 
addition, we have clearly verified that in POI, where inflamma-
tion only occurs in the muscularis externa the intestinal vagal 
anti-inflammatory effect is independent of the spleen and of 
ACh-producing T cells. As in the spleen, immune cells in the gut 
wall are indirectly modulated by the VN as vagal efferents solely 
synapse with cholinergic enteric neurons in the myenteric plexus 
(31). This implies that enteric neurons rather than vagal nerve 
endings interact with the intestinal immune system and release 
ACh.
Over the years, it is becoming increasingly clear that the 
microenvironment in the gut mucosa and submucosa determines 
the immune response to the initial exposure of luminal antigens. 
Given the potent anti-inflammatory effect of the cholinergic 
innervation, one might assume that the cholinergic tone in the 
submucosal compartment may have an important impact on 
mucosal immune homeostasis. The ENS forms a dense network 
of nerve fibers in close vicinity with intestinal immune cells, both 
in the submucosal (lamina propria) and muscularis externa com-
partment of the intestine (33). This could imply that vagal signals 
are amplified by the ENS inducing a substantial release of ACh 
in the intestinal microenvironment leading to modulation of the 
immune response. In line with this hypothesis, electrical and 
pharmacological activation of CAIP has been widely studied as a 
novel approach to treat IBD in several animal models. Reduced 
vagal cholinergic input induced by abdominal vagotomy results 
in an increased susceptibility to develop colitis with an elevated 
proinflammatory cytokines production following dextran sulfate 
sodium (DSS) administration (34). In line, nicotine or α7nAChR 
specific agonist treatments were protective in experimental 
colitis (34, 35). In addition, reduced mucosal levels of ACh in a 
murine model of depression were also associated with exacerba-
tion of colitis (36, 37). However, the actual determinant of the 
increased susceptibility to colitis after vagotomy is still unknown. 
Interestingly, O’Mahony et al. recently showed that vagotomized 
mice have basal increase of activated nuclear factor (NF)-κB level 
in the gut and reduced splenic Tregs (38).
However, the crucial role of the α7nAChR revealed in models 
of sepsis and POI still remains ambiguous in colitis. α7nAChR−/− 
mice had a higher severity of acute DSS-induced colitis which 
was in line with choline-chloride (α7nAChR specific agonist) 
treatment able to decrease inflammatory parameters in a model 
of depression-induced colitis (37). On the other hand, Snoek 
et al. described that treatment with specific α7nAChR agonists 
(AR-R17779 and GSK1345038A) reduced inflammation, such 
as NF-κB activity and cytokines, but these treatments did not 
improve the clinical signs of colitis (39), indicating that during 
colitis the receptor involved in vagal anti-inflammatory effect is 
still uncertain.
In accordance with the ambiguous effect of α7nAChR in 
experimental models of colitis, nicotine, an ACh nicotinic receptor 
agonist, has an opposite effect in the two main IBD forms: ulcera-
tive colitis (UC) and Crohn’s disease (CD). Clinical observation 
indicates that UC patients experience more severe disease upon 
quitting smoking, while it improves again after returning to smoke 
(40, 41). In addition, a lower incidence of UC has been observed 
in smokers, while a negative effect of cigarette smoking has been 
observed in CD patients (41, 42). Smoking, namely, worsened 
symptoms compared to non-smokers in CD patients (43) due to 
increased influx of neutrophils into the intestinal mucosa (44, 
45), suggesting that nicotine might affect colonic inflammation in 
IBD via CAIP. Galitovskiy et al. proposed a possible experimental 
explanation for the dichotomous effect of nicotine in colitis. In 
this study, the authors showed that nicotine attenuated oxazolone 
colitis, resembling UC (Th2-induced inflammation), increasing 
colonic regulatory T cells and reducing Th17 cells. On the con-
trary, nicotine exacerbated trinitrobenzene sulfonic acid (TNBS-) 
induce colitis, resembling CD (Th1-induced inflammation), by 
The gastrointestinal tract is highly innervated via the autonomic nervous system (sympathetic and parasympathetic system) and enteric nervous system (via the 
myenteric and submucosal plexus). While the parasympathetic fibers (vagus nerve) extensively innervate the gut wall up to the myenteric plexus, the sympathetic 
fibers directly contact immune cells, secondary lymphoid organs (such as isolated lymphoid follicles), and enteric fibers in the submucosal/mucosal compartment (A). 
Innate and adaptive immune cells, such as dendritic cells (DCs), macrophages (MFs), and T cells, located in the mucosal villi are affected by the presence of several 
immune-modulating neurotransmitters released by the enteric neural fibers, such as substance P (SP), vasoactive intestinal peptide (VIP), serotonin (5-HT), and 
neuropeptide y (NPY) (B). In the myenteric plexus, a dense network of enteric neurons is present in close proximity to resident macrophages. The release of 
acetylcholine (ACh) and multiple of neuropeptides (SP, VIP, 5-HT, and NPY) condition the resident macrophages residing in the myenteric plexus (C). During 
inflammation, vagal efferent fibers directly activate cholinergic enteric neurons in the myenteric plexus. The release of ACh triggers α7 subunit of the nicotinic 
acetylcholine receptor (α7nAChR) expressed on resident macrophages. The activation of α7 nAChR decreases tumor necrosis factor alpha (TNFα) release and 
favors regulatory T cells (Treg) conversion (our observation) leading to the control of intestinal inflammation and restoration of intestinal immune homeostasis (D).
FiGURe 2 | Continued
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increasing colitogenic Th17 cells (46). These findings suggest that 
nicotine might influence the inflammation according to the type 
of immune response partially explaining the controversial effect 
of smoking observed in UC and CD patients.
Various studies have tried to correlate autonomic dysfunction, 
such as alteration of the vagal tone, with clinical outcome in IBD 
patients (47, 48). Bonaz and colleagues reported negative correla-
tion between low vagal tone and increase plasma levels of tumor 
necrosis factor alpha (TNF-α), suggesting that the CAIP may be 
altered in these patients. However, a clear correlation between IBD 
and vagal tone has still not been convincingly verified. Recently, 
Clarençon et al. described the first attempt of VNS in a patient 
with CD. The patient subjected to long-term low frequency VNS, 
showed significant improvement with reduction of both clinical 
disease activity index and endoscopic remission. This beneficial 
effect was correlated to an increased parasympathetic tone (49). 
Even though this report is interesting in this patient proposing a 
therapeutic role for the VNS in IBD, results should be taken with 
caution considering the size of the study and the fact that placebo 
effect could not be ruled out using this experimental approach.
Currently, electrical VNS is explored as therapeutic treatment 
in patients affected by chronic inflammation (50). Ongoing clini-
cal trials are investigating the possible beneficial effect of VNS in 
patients with RA, POI, and CD (NCT01552941, NCT01569503, 
and NCT01572155). Additional preclinical and clinical data will 
hopefully clarify whether the CAIP will be an alternative thera-
peutic approach to treat intestinal inflammatory diseases.
SYMPATHeTiC NeRvOUS SYSTeM
Besides the PNS, the GI tract is extensively innervated by the 
sympathetic nervous system (SNS) mostly involved in the modu-
lation of blood flow, secretion, and motility.
Sympathetic fibers mainly innervate the myenteric and 
submucosal plexus as well as the mucosal layer (51). Of note, 
on the contrary to the PNS, sympathetic fibers have been found 
in direct contact with immune cells residing in gut-associated 
lymphoid tissues including Peyer’s patches and MLN (52, 53). 
Anatomical studies have undoubtedly shown large amounts of 
noradrenergic fibers both into the dome region of the follicles 
where fibers are in direct contact with lymphoid cells and in the 
lamina propria where fibers are mainly associated with blood ves-
sels (52). Interestingly, various innate and adaptive immune cells 
express receptors for the typical sympathetic neurotransmitters, 
including noradrenaline (NA) and adrenaline (A), supporting 
the idea that also the SNS may regulate immune response and 
inflammation in peripheral tissues including the GI tract (25, 54, 
55). Catecholamines bind a large family of adrenergic receptors. 
These are G-couple receptors composed of different subunits: 
three α1 (A, B, and D), three α2 (A–C), and three β (β1–β3) 
receptor subtypes. Interestingly, adrenergic receptors have dif-
ferent threshold of activation depending on the cathecholamine 
concentration: high concentrations activate β-adrenoreceptors, 
subsequently increasing cAMP levels, whereas low concentra-
tions activate preferentially α-adrenoreceptors leading to 
decreased cAMP levels (56). This difference may explain the 
controversial results obtained in experimental and clinical studies 
investigating the pro- and anti-inflammatory role of sympathetic 
innervation during local tissue inflammation. It is important to 
mention that catecholamines can also be produced and released 
by various immune cells, such as T- and B-cells (57). Interestingly, 
production of catecholamines after immune cell activation has 
been proposed as an autocrine loop involved in the regulation of 
inflammation (58).
Together with anatomical proximity of noradrenergic fibers to 
various immune cells (59), also a direct functional interaction has 
been proven on DCs. Recent studies, demonstrated direct effects 
of NA on DC migration, antigen uptake, cytokine production and 
T cell polarization via the intracellular signaling pathways PI3K 
and ERK1/2 (60–63). Additionally, adrenergic fibers also affect T 
cell polarization repressing Th1 polarization, while favoring Th2 
cell induction (64, 65), suggesting possible effect of NA in the 
skewing of T cell responses.
The reciprocal cross-talk between the sympathetic fibers and 
immune system has been extensively studied also in experimental 
models of intestinal inflammation.
In order to study the role of sympathetic immune-regulation 
during inflammation, chemical sympathectomy has been 
performed using 6-hydroxydopamine (6-OHDA) treatment 
resulting into depletion of NA in the peripheral nerve terminals. 
In rats, 6-OHDA treatment revealed an alteration in migration 
and accumulation of lymphocytes (B and T cells) in the gut-
associated lymphoid organs during inflammation (66, 67). In 
more detail, sympathetic denervation decreased inflammation in 
acute DSS- and TNBS-induced colitis (68, 69). On the contrary, 
Straub and colleagues showed in two different chronic models of 
colitis (i.e., chronic DSS-induced colitis and IL10-deficient mice) 
that chemical sympathectomy significantly exacerbated disease, 
suggesting that catecholamines may play a favorable effect in the 
chronic phase of inflammation by promoting tissue repair (70). 
These controversial results might be explained by a dual role of 
these fibers in which the SNS confers proinflammatory effects 
at the beginning of colonic inflammation, while it exerts anti-
inflammatory effects in the chronic phase of inflammation. Of 
note, similar results have been recently described in a murine 
model of rheumatoid arthritis, another chronic model of inflam-
mation. Indeed, mice that underwent early sympathectomy 
showed improvement of arthritis scores while animals subjected 
to late sympathectomy had significantly increased arthritis scores 
compared with control mice (71).
In addition to sympathectomy, several studies have attempted 
to mimic the effect of the SNS during colitis by pharmacologi-
cal activation of adrenergic receptors. Treatment with a β3-AR 
agonist was shown to be beneficial as it reduced the severity of 
TNBS-induced colitis in rat (72). However, this anti-inflamma-
tory effect of the agonist might be indirect, since it was associated 
with cholinergic-mediated contractions of the colon known to 
improve mucosal healing (73). However, in another study activa-
tion of β3-ARs was also able to reduce colonic cytokines release, 
further supporting its anti-inflammatory effect in colitis (51). 
Additionally, during TNBS-induced colitis, mice treated with α2-
adrenoceptor antagonist, RX821002, showed a reduced expres-
sion of colonic proinflammatory genes (TNF-α and IL-1β) (74). 
Overall, preclinical data clearly indicate the immunomodulatory 
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effect of the SNS in experimental models of colitis. However, the 
effect of the SNS is still controversial with studies reporting both 
pro and anti-inflammatory effects, depending on the preclinical 
model used and on the disease stage assessed (69).
As previously mentioned, accumulating evidence suggests 
that abnormalities in the neural autonomic profile may be an 
aggravating factors in the pathogenesis of IBD (50). Of note, 
enzymes involved in the synthesis of NA are reduced in patients 
affected by both UC and CD even though lower level of NA has 
been only detected in CD patients (75, 76). Furthermore, a reduc-
tion of sympathetic nerve fibers has been observed in biopsies 
from CD patients, while sympathetic fibers are increased in tissue 
of UC patients (77, 78).
The idea that SNS dysfunction may have an impact on IBD 
has been recently tested with promising results in a clinical trial 
in UC patients. In this study, treatment with the α2-AR-agonist 
clonidine, induced normalization of the SNS activity and signifi-
cantly improved disease severity in patients with active UC (79).
Although the involvement of the SNS in the inflammatory 
response has been extensively proven, further studies should be 
conducted to better understand how modulation of the SNS may 
enter in the therapeutic armamentarium of IBD.
THe PePTiDeRGiC PATHwAY: 
NeUROPePTiDeS
Neuropeptides are neuronal signaling peptides involved in a wide 
range of neuronal functions. Often neuropeptides are coreleased 
with neurotransmitters complicating studies evaluating their spe-
cific effects. Neuropeptides modulate neuronal communication 
by acting on cell surface receptors. Interestingly, various subtypes 
of neuropeptide receptors are also expressed on immune cells 
suggesting possible influence of these molecules on the immune 
system (Table 1). This idea is supported by clinical and experi-
mental observations obtained in IBD patients and animal models 
of colitis that are discussed below.
vASOACTive iNTeSTiNAL PePTiDe
Vasoactive intestinal peptide is a 28-amino acid neuropeptide 
that is widely expressed in different tissues, including intestine, 
central and peripheral nervous system, pancreas, and lung (80). 
In the intestine, VIP is mainly produced by enteric neurons in the 
myenteric and submucosal plexus and regulates both intestinal 
motility and chloride secretion (81, 82, 84). In addition, VIP 
has emerged as a potent anti-inflammatory peptide affecting 
both innate and adaptive immune responses. Due to its anti-
inflammatory properties, the therapeutic potential of VIP in 
the treatment of inflammatory disorders, such as IBD, has been 
extensively investigated. In the intestine, the receptors for VIP 
(VPAC1 and VPAC2), are mainly expressed by smooth muscle 
cells and immune cells including T cells, DCs, and MFs, suggest-
ing a possible immune-modulatory effect of VIP (80, 83, 85). The 
in vitro anti-inflammatory properties of VIP on myeloid cells are 
well documented and highly relevant for IBD. Indeed, one of the 
proposed pathogenic drivers in IBD is the loss of immune toler-
ance against harmless antigens leading to chronic production 
of inflammatory mediators by MFs and enhanced Th1/Th17 
polarization by inflammatory DCs (149, 150). Interestingly, 
VIP inhibits inflammatory MFs through inhibition of NF-κB 
activation leading to reduced production of proinflammatory 
cytokines (TNFα, IL-6, and IL12p40) and enhanced production 
of the tolerogenic cytokine IL-10 (151–155). Moreover, VIP treat-
ment reduces expression of toll-like receptor 4 (TLR4) in MFs 
rendering them less responsive to lipopolysaccharide (LPS) (86, 
87). In addition, DCs acquire an anti-inflammatory phenotype 
upon VIP treatment. VIP-induced activation of VPAC1 in bone 
marrow-derived DCs induces a tolerogenic phenotype with low 
levels of costimulatory molecules CD80, CD86, and CD40, and 
high levels of the anti-inflammatory cytokine IL-10 (88, 89). 
These VIP-conditioned DCs induce polarization of naïve CD4+ 
T cells into CTLA4pos IL-10 secreting Tregs. In addition to its 
effects on innate immune cells, VIP also acts directly on T cells 
to promote Th2 differentiation through activation of VPAC2 (90, 
91). Notably, during Th2 differentiation both VIP and VPAC2 are 
upregulated in T cells, suggesting that VIP-VPAC2 participates in 
a Th2 autoregulatory loop (92). It has indeed been demonstrated 
that VIP supports survival of Th2, but not Th1 cells (90). Taken 
together, by acting on both the innate and adaptive arm, VIP 
actively counteracts Th1 responses. These findings highlight VIP 
as an attractive therapeutic candidate for the treatment autoim-
mune disorders with a typical Th1 profile, including CD. The 
therapeutic potential of VIP in CD is indeed supported by the 
beneficial effects of VIP in TNBS-induced colitis, an experimen-
tal model of CD (156). Administration of VIP induces a remark-
able amelioration of TNBS-induced colitis through activation of 
VPAC1. Reduced disease severity correlates with lower levels of 
proinflammatory chemokines and cytokines, inhibition of Th1 
responses and induction of a Th2 immune response (156, 157). 
Although VIP showed very profound effects in this study, it should 
be noted that other studies could not confirm the beneficial effects 
of VIP in TNBS-induced colitis (158). Moreover, inhibition or 
genetic deletion of VIP does not exacerbate colitis, but rather 
induces resistance to both TNBS- and DSS-induced colitis (93, 
159). These findings make the interpretation of the preclinical 
therapeutic evidence of VIP in colitis difficult and argue for fur-
ther fundamental research to better understand the promiscuous 
role of VIP in intestinal physiology and pathology. Also from a 
clinical point of view, the role of VIP in IBD is far from clear. 
Although there are some reports showing hypertrophic VIPergic 
nerves and increased VIP levels in rectal biopsies of patients with 
IBD, other reports demonstrate no increase or even decreased 
levels of VIP (94–96). In summary, although VIP exerts potent 
anti-inflammatory effects in vitro, there is currently not enough 
preclinical and clinical evidence to support translation of VIP 
treatment in IBD to the clinic.
NeUROPePTiDe Y
Neuropeptide Y is a 36-amino acid peptide and is considered as 
one of the most abundant peptides in the central and peripheral 
nervous system (97). NPY is highly conserved among species and 
in mammals its effects are mediated trough binding of six differ-
ent G-coupled receptor subtypes (Y1, Y2, Y3, Y4, Y5, and Y6) (98, 
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99). In the CNS, NPY is mainly present in the hypothalamus and 
is involved in modulating anxiety, appetite, blood pressure, and 
nociception (160–162). On the other hand in the periphery, it is 
mainly expressed in sympathetic nerves where it is colocalized 
and coreleased with NA. Within the gut, enteric neurons of the 
myenteric plexus and submucosal plexus are the major source of 
NPY (163). The biological effects of NPY on the GI system are 
of inhibitory nature and include effects on pancreatic and GI 
secretion, blood pressure, and GI motility as well as modula-
tion of intestinal inflammation with direct interaction with 
the immune system (164). NPY can affect both the cells of the 
innate and adaptive immune system as it modulates neutrophil 
chemotaxis, granulocyte oxidative burst, and NO production, T 
helper cell differentiation, natural killer cell activity, suppression 
TABLe 1 | expression and effect of selected neurotransmitters during intestinal inflammation.
Neurotrasmitter Main source Receptors Target cells experimental evidence Clinical evidence
Catecholamines
Noradrenaline–
adrenaline
Sympathetic 
fibers, T and B 
cells (59)
β-adrenoreceptors 
(58)
α-adrenoreceptors 
(58)
DCs, T cells (25, 56, 57) Sympathetic denervation improves DSS, 
TNBS (78, 79)
Sympathetic denervation worsens  
IL10−/− and chronic DSS (77, 80, 81)
β3-AR agonist improves TNBS (82)
α2-Adrenoceptor antagonist improves 
TNBS (83)
Active UC patients typically 
have increased SNS activity 
(71–73), it is decreased in CD 
patients (74)
α2-AR-agonist improve 
severity of UC in human (71)
Acetylcholine Parasympathetic 
fibers
Cholinergic enteric 
neurons
T and B cells
(23–27)
α7 nicotinic 
acetylcholine 
receptor (26)
Macrophages (22, 26, 31) Vagotomy worsens DSS (34)
Choline-chloride improves depression-
induced colitis (37)
Nicotine improves oxazolone colitis (46)
Nicotine worsens TNBS (46)
α7nAChR−/− mice had a higher severity  
of acute DSS-induced colitis (39)
VNS improves severity CD 
patient (49)
Neuropeptides
Vasoactive 
intestinal  
peptide (VIP)
Enteric neurons 
(81)
VPAC1, VPAC2 
(80)
Smooth muscle, T cells, 
DCs, macrophages (80–82, 
84, 85)
Immunomodulatory effects (86–92)
VIP treatment ameliorates TNBS  
colitis (93)
Limited clinical evidence: 
both ↑ and ↓ of VIP level 
observed in IBD (94–96)
Neuropeptide Y 
(NPY)
Central and 
peripheral nervous 
system (97)
Immune cells (105)
Y1, Y2, Y3, 
Y4, Y5, and Y6 
(GPCRs) (98, 99)
Innate and adaptive 
immune cells (monocytes, 
lymphocytes, and 
granulocytes) (100–103)
Proinflammatory effect: shown in mouse 
and rat models of DSS
Induced colitis (106–108) and TNBS-
induced colitis (109)
IBD patients: no change in 
NPY plasma levels (104)
Calcitonin  
gene-related 
peptide (CGRP)
α-CGRP: central 
and peripheral 
nervous system
β-CGRP: gut, 
pituitary gland, 
and immune 
system (119–121)
Calcitonin 
receptor-like 
receptor (CRLR) 
(110)
TRPV1 and CGRP are 
colocalized on peripheral 
neurons and on immune 
cells, such as MFs and DCs 
(111–115)
Anti-inflammatory effect
Shown in mouse and rat models of  
DSS-induced colitis (122) and TNBS-
induced colitis (123)
UC and CD patients: ↓ 
CGRP+ cells in the intestinal 
muscularis layer (116–118)
Substance  
P (SP)
Central and 
peripheral nervous 
system (124–126)
Innate immune 
cells: monocytes, 
MFs, eosinophils 
and lymphocytes 
(133–136)
Neurokinins-1 
(NK-1), NK-2, and 
NK-3 (GPCRs) 
(127–130)
Enteric neurons, smooth 
muscle, endothelial cells, 
immune effectors, and 
mucosal epithelial cells 
(127–130)
Contradictory results
Proinflammatory effect: shown in  
mouse and rat models of DSS colitis 
(137) and TNBS colitis (138)
Anti-inflammatory effect: role in mucosal 
healing shown in mouse models of  
DSS and TNBS colitis (140, 141)
UC patients
↑ SP in rectum and colon (77, 
131, 132)
SP in severe inflammatory 
colon lesions (139)
CD patients: decreased 
(131), unchanged (142), and 
increased (77) SP levels
Serotonin Enterochromaffin 
cells, enteric 
neurons (143, 144)
5-HT receptors 
(143, 144)
Enteric neurons, immune 
cells (145, 146)
↓ Serotonin (genetic and 
pharmacological) ameliorates DSS and 
DNBS colitis (147); ↑ serotonin worsens 
colitis in IL10−/− mice (148)
No clinical evidence available
of lymphocyte proliferation and activation of APCs (165–168). 
Interestingly, next to nerve-derived NPY, immune cells them-
selves are able to express NPY enabling them to modulate the 
immune cell function in a paracrine or autocrine manner (105). 
The expression of several Y receptor subtypes have been reported 
on immune cells (100–103). As Y1 receptor is the most abundant 
receptor, it has been intensively investigated and appears to be 
present in each immune cell investigated so far (100). Although 
less information has been gathered about the expression of other 
Y receptors, human neutrophils express Y1, Y2, Y4, and Y5, 
with Y4 being the most abundant (169). Furthermore, Y1, Y2, 
and Y5 expression was also demonstrated in mouse MFs and rat 
granulocytes (103, 170). NPY can exert pro- or anti-inflamma-
tory effects, depending on which receptor is activated and on 
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which immune cell. In particular, NPY levels were shown to be 
increased in both DSS-induced colitis (171) and TNBS-induced 
colitis (109). Further evidence for the role of NPY in promoting 
inflammation in the gut is provided by the fact that NPY knock-
out (KO) mice are resistant to the induction of DSS colitis (106, 
107). Similar results were obtained by using an NPY antisense 
oligodeoxynucleotide in rats (171). Receptor Y1 seems to mediate 
the proinflammatory effect of NPY as KO or antagonism of the 
receptor results into a comparable attenuation of inflammation 
(108). In addition, receptor Y1-deficient mice have impaired 
APC function and consequently a decreased number of effector 
T cells, as well as a decreased MF production of TNF-α and IL-12, 
explaining the observed protective phenotype in experimental 
colitis (102). During gut inflammation, there is a considerable 
amount of cross-talk between NPY and TNF-α. This was shown 
by the decreased production of TNF-α by enteric neuronal cells 
from NPY-deficient mice. Conversely, block of TNF-α causes a 
reduction in colonic NPY expression (172). Additionally, NPY 
also enhances nNOS, which is associated with oxidative stress, in 
a murine model of DSS colitis (106). Although NPY plasma level 
is not altered in IBD patients (104), targeting NPY or its receptors 
might be an interesting therapeutic approach for treating IBD.
CALCiTONiN GeNe-ReLATeD PePTiDe
Calcitonin gene-related peptide (CGRP) is a 37-amino acid 
neuropeptide that exists in two isoforms, α-CGRP and β-CGRP. 
These isoforms are encoded by two different, but closely related 
genes. α-CGRP is mainly produced in the central and peripheral 
nervous system, whereas β-CGRP is primarily produced in the 
gut, pituitary gland and by immune cells. The biological actions 
of both isoforms are largely overlapping (119–121). Although 
CGRP participates in development and maintenance of pain, it 
has been also described as a potent regulator of inflammatory 
responses (173). In addition in the GI tract, CGRP participates 
in the regulation of gastric acid secretion and intestinal motil-
ity (174, 175). Release of CGRP by nerve endings and immune 
cells is induced by activation of the transient receptor potential 
vanilloid 1 (TRPV1). TRPV1 and CGRP are colocalized on 
peripheral neurons as well as on immune cells, such as MFs 
and DCs (111–115). Whereas the anti-inflammatory effect of 
CGRP on LPS-induced inflammation is well described, its role 
in intestinal inflammation still needs to be fully elucidated. Up 
to now numerous studies have pharmacologically investigated 
the role of CGRP in experimental models of colitis. The effect of 
systemic administration of CGRP and its antagonist, hCGRP, has 
been tested in a rat TNBS model. Intravenous administration of 
CGRP protected the colonic mucosa against TNBS in both the 
early and late phases of acute colitis, while hCGRP exacerbated 
TNBS-induced inflammation (123). On the other hand, the con-
tribution of TRPV1 in gut inflammation is still controversial, as it 
was shown that disease severity was reduced in TRPV1 KO mice 
in model of DSS colitis, suggesting that TRPV1 activation may 
enhances inflammation (176). On the contrary, acute stimula-
tion of sensory neurons by capsaicin, a known TRPV1 agonist, 
ameliorated disease symptoms in TNB-colitis in rats (177). This 
could be due to the corelease of other neuropeptides from sensory 
TRPV1+ fibers, such as substance P, which could promote a more 
proinflammatory milieu (122). Recently, CGRP expression has 
also been reported in TRPM8 expressing (temperature-sensitive 
TRP channels for cold sensation) mucosal fibers. In line, TRPM8-
dependent CGRP release have been shown in the colon upon DSS 
exposure (122). In the same study, genetic deletion of TRPM8 
increased the susceptibility of mice to acute colitis. This was cor-
related with an increase in CGRP levels in mucosal fibers suggest-
ing that TRPM8-CGRP signaling may be involved in dampening 
intestinal inflammation (122).
Considering the possible participation of CGRP in the patho-
genesis of IBD many studies have attempted to gather clinical data 
in both UC and CD patients. However, while early studies showed 
a decrease of CGRP positive cells in the intestinal muscularis 
layer of UC and CD patients (116–118), a more recent report did 
not confirmed lower CGRP level in tissue from patients during 
moderate and severe UC (178).
SUBSTANCe P
Substance P is a neuropeptide which is composed of 11-amino 
acids (179) and is widely expressed in the brain and periphery 
(124) including the GI tract where it is mainly expressed by neu-
rons of the myenteric and submucosal plexuses, as well as intrinsic 
and extrinsic sensory neurons (125, 126). Interestingly, SP is also 
expressed by a variety of innate immune cells, such as monocytes 
(133), MFs (136), eosinophils (134), and lymphocytes (135). SP 
binds specific G protein-coupled receptors named neurokinins-1 
(NK-1), NK-2, and NK-3. Within these three receptors, NK-1 has 
the highest affinity for SP and is abundantly expressed through-
out the GI tract by different kind of cells: enteric neurons, smooth 
muscle, endothelial cells, immune effectors, and mucosal epi-
thelial cells (127–130). Several studies have correlated SP-NK-1 
signaling with intestinal inflammation. In a model of TNBS 
colitis, mice lacking neutral endopeptidase (NEP), an enzyme 
that degrades SP in the extracellular fluid, displayed exacerbated 
inflammation (138). Accordingly, the use of an NK-1 antagonist 
improved the severity of colitis in different experimental models 
(137, 138). Binding of SP to its receptors leads to the activation 
of mitogen-activated protein (MAP) kinase, protein kinase C 
(PKC), and NF-kB pathways leading to production of proinflam-
matory cytokines, such as IL-1b, IL-6, IL-8, and TNFα (180–183). 
Although these findings suggest a proinflammatory effect of SP 
in intestinal inflammation, studies have emerged that highlight a 
role for SP in mucosal healing and thus propose a beneficial effect 
of SP in colitis. Castagliuolo I et al. described the development of 
DSS and TNBS-induced colitis in NK-1 receptors deficient mice, 
and showed that there was an increase in severity of colitis as 
well as an increased mortality in these mice (140). The protective 
effect of NK-1 is associated with the transactivation of epidermal 
growth factor receptor (EGF-R), which in turn leads to cell prolif-
eration in the colon (140, 141). Moreover, SP has been described 
to trigger cell proliferation in a multitude of cell types, such as 
T cells, smooth muscle cells (184). Although clinical evidence 
suggests a role for SP in the pathophysiology of IBD in patients, 
the exact role of SP in intestinal inflammation needs to be further 
elucidated. Several studies investigated levels of SP in the serum 
November 2015 | Volume 6 | Article 59010
Di Giovangiulio et al. Neuroregulation of the Intestinal Immune System
Frontiers in Immunology | www.frontiersin.org
and locally in the gut. Increased levels of SP have been observed 
in the rectum and colon of UC patients, and were correlated with 
disease activity (77, 131, 132). On the other hand, another study 
showed that SP containing nerves increased in hypervascularized 
lesions, while they decreased in severe inflammatory lesions in 
the colon of UC patients (139). Contradictory results have also 
emerged in studies investigating SP in CD patients. While some 
reported decreased levels of SP in the mucosa in CD patients (131), 
others showed that there is no difference (142) or even an increase 
in SP levels (77). These controversial results might be explained 
by the variation in methodology, tissues used and different stages 
of the disease (185–187). Additionally, changes in NK-1R expres-
sion were investigated in IBD patients. An increased number of 
NK-1R positive lymphoid cells was observed and additionally 
also increased NK-1R mRNA expression in inflamed mucosa was 
reported. Furthermore, an altered pattern of epithelial NK1-R 
expression was found in UC, while in CD an increased expres-
sion was reported in the myenteric plexus (125). Clearly, further 
studies are needed in order to clarify the interaction between SP 
and the immune system and its possible involvement in intestinal 
inflammation.
SeROTONiN
Although serotonin or 5-hydroxytryptamine (5-HT) is well 
known as a neurotransmitter of the CNS, the majority of serotonin 
in the human body is produced in the GI tract (143). Intestinal 
5-HT is mainly produced by enterochromaffin cells (ECs) and 
enteric neurons of the myenteric plexus (144, 188). In both cells 
types, biosynthesis of 5-HT depends on the conversion of dietary 
l-tryptophan to 5-hydroxytryptophan by tryptophan hydroxylase 
(TPH). Synthesis of 5-HT in the intestine is performed by two 
different types of TPH, namely TPH1 and TPH2 (145). The bulk 
of 5-HT is produced by ECs and depends on TPH1. In contrast, 
enteric neurons only have a minor contribution to total 5-HT levels 
in the intestine and rely on TPH2 for the production of 5-HT. The 
distinct regulation of 5-HT synthesis in these two compartments 
also has important functional implications. Whereas myenteric 
production of 5-HT by TPH2 is essential for normal motility, 
mucosal 5-HT synthesis by TPH1 in ECs influences intestinal 
inflammation (145, 147). Indeed, depletion of mucosal 5-HT via 
genetic deletion ameliorates both DSS- and DNBS-induced colitis 
in mice. This effect is eliminated when TPH1 knockout mice are 
replenished with 5-HT (147). In line, mice that develop spontane-
ous colitis due to IL-10 deficiency have increased disease severity 
when the actions of 5-HT are amplified by genetic deletion of the 
serotonin transporter SERT (148). Enterocytes of SERT knockout 
mice are unable to remove 5-HT from the extracellular space 
leading to enhanced 5-HT effects. Taken together, these data 
clearly show that mucosal 5-HT has profound proinflammatory 
effects and can exacerbate development of colitis. Hence, selec-
tive inhibition of mucosal 5-HT levels might be an interesting 
therapeutic option for the treatment of IBD. In a recent study, the 
therapeutic potential of selective TPH1 inhibition has been vali-
dated. Indeed, oral administration of telotristat etiprate, a potent 
TPH1 inhibitor, effectively reduced disease severity and intestinal 
inflammation in mice with TNBS-induced colitis (146). Of note, 
telotristat etiprate did not cross the blood–brain barrier nor did 
it affect serotonin levels in myenteric neurons (189, 190). This is 
important to ensure the safety of the treatment and to avoid side 
effects due to depletion of 5-HT in the CNS and ENS. Another 
way to reduce the proinflammatory effects of 5-HT is by inhibi-
tion of 5-HT receptors that are selectively expressed on intestinal 
immune cells. Although the mechanisms by which 5-HT exerts 
its proinflammatory actions is not completely understood, it 
was recently shown that DCs isolated from TPH1 deficient mice 
produce less IL-12 compared to wild-type DCs (191). Treatment 
of these DCs with 5-HT led to restoration of IL-12 production, 
indicating that 5-HT can polarize DCs to become proinflamma-
tory. Hence, selective pharmacological inhibition of 5-HT might 
be an interesting therapeutic approach since the proinflam-
matory actions of 5-HT on intestinal DCs could be reduced. 
Unfortunately, the 5-HT receptors that are commonly found on 
intestinal DCs are also involved in other processes in both CNS 
and ENS. Accordingly, inhibition of 5-HT receptor signaling 
has a relatively poor therapeutic potential given the severe side 
effects, including behavioral and motility problems. In summary, 
reduction of mucosal 5-HT through selective inhibition of TPH1 
likely holds most promise for future treatment of inflammatory 
intestinal disorders. However, further research is needed to bet-
ter define the cellular players involved in the proinflammatory 
actions of 5-HT.
CONCLUSiON AND PeRSPeCTive
An intricate network of immune and non-immune cells and their 
mediators function in unison to protect us from toxic elements 
and infectious microbial diseases that are encountered in the 
intestinal lumen. This network operates efficiently by use of a 
single cell epithelium layer, fortified by adjacent cells and lym-
phoid tissues that protect its integrity. On occasion alterations of 
the steady state due to genetic background and/or environmental 
microbes result in inflammatory diseases or infections includ-
ing development of IBD. Thus, intestinal immune homeostasis 
is finely regulated by several redundant strategies to counteract 
excessive and unnecessary immune responses. Lately, an intimate 
bidirectional interaction between the nervous and immune sys-
tem in the gut has been increasingly demonstrated. This pathway 
is a hard-wired connection between the immune and nervous 
system closely interacting to regulate inflammation. Based on 
our and others’ findings, we can now conclude that intestinal 
neuronal circuits modulate the immune response directly into the 
gut wall. Therefore, we hypothesize that there may be two stages 
of neural modulation in the gut: in case of subtle and localized 
intestinal inflammation, the local innervation involving the ENS 
will be activated, while in more systemic inflammatory responses, 
such as in severe colitis, the autonomic innervation will come into 
play and modulate the immune response even in distant organs, 
such as the spleen or the bone marrow.
In conclusion, studying the immune-modulatory properties 
of nervous systems as well as endogenous neuropeptides will 
be a fundamental challenge for the next years. Although further 
fundamental understanding of their role in specific immune 
disorders is required, it is evident that neuroimmunomodulatory 
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therapies hold great promise, as evidenced by the ongoing clini-
cal trials evaluating the effect of CAIP in autoimmune disorders. 
Further understanding of the neuronal circuits and receptors 
involved will likely support the development and use of specific 
receptor agonists and antagonists in the treatment of different 
neuroimmune pathologies. These new insights will not only affect 
our understanding of GI function, but might help to elucidate the 
complex interactions in other organs and systems. Unraveling of 
the mechanisms by which the autonomic and intrinsic innerva-
tion may reinstall intestinal immune homeostasis will, therefore, 
have a major impact on the therapeutic approach of many so far 
untreatable disorders, such as IBD.
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